Skip to main content
. 2016 Aug 18;11(9):1536–1544. doi: 10.2215/CJN.00910116

Figure 1.

Figure 1.

Receiver-operating characteristics analyses for predicting AKI progression or AKI progression with death. (A) The area under the receiver operating curve (AUCs) of renal injury biomarkers (urinary angiotensinogen [uAGT], urinary neutrophil gelatinase-associated lipocalin [uNGAL], urinary IL-18 [uIL-18]) and clinical model, at the time of AKI diagnosis, for predicting AKI progression. (B) The AUCs of renal injury biomarkers (uAGT, uNGAL, uIL-18) and clinical model, at the time of AKI diagnosis, for predicting AKI progression with subsequent death. (C) The performance of combination of renal injury biomarkers for predicting AKI progression. The clinical risk model includes age, gender, hypertension, diabetes, preadmission eGFR, N-terminal pro-B-type natriuretic peptide (NT-proBNP), serum albumin, hemoglobin, diuretic dosage before AKI, use of spironolactone before AKI, use of RAS inhibitors before AKI, and change of serum creatinine from baseline at the time of AKI diagnosis.